It has been shown that ERCC1 expression was significantly associated with longer survival in the group of BC patients without adjuvant chemotherapy, while ERCC1 positivity was associated with shorter survival in patients receiving adjuvant chemotherapy [62], indicating that administration of adjuvant chemotherapy has a clinical significance in patients with ERCC1 negative tumours. Here, ERCC1 is linked to breast cancer.